Inhibition of tumor necrosis factor-alpha release in rat experimental endotoxemia by treatment with the 21-aminosteroid U-74389G

Crit Care Med. 1999 Jun;27(6):1164-7. doi: 10.1097/00003246-199906000-00044.

Abstract

Objective: To determine the effect of the 21-aminosteroid U-74389G on tumor necrosis factor (TNF)-alpha release in experimental endotoxemia.

Design: Prospective, randomized, controlled animal study.

Setting: Experimental laboratory.

Subjects: Twenty-one male Wistar rats weighing 190+/-40 g.

Interventions: The rats were divided equally into 3 groups: a) control; b) endotoxemia (5 mg/kg lipopolysaccharide [LPS] from Escherichia coli 055:B5); and c) endotoxemia and U-74389G administration 30 mins before (3 mg/kg) and 60 mins after (1.5 mg/kg) endotoxin challenge.

Measurements and main results: At 0, 120, and 240 mins, serum levels of TNF-alpha were measured using a specific rat TNF-alpha ELISA kit. U-74389G-treated endotoxemic animals showed significantly reduced TNF-alpha release 120 mins after endotoxin challenge (control, 2.5+/-2.1 pg/mL; LPS, 4041+/-871 pg/mL; U-74389G, 1627+/-474 pg/mL [p < .05]). Two hundred forty minutes after LPS administration, TNF-alpha levels decreased, whereas values in the untreated LPS group remained twice as high as those in the U-74389G group (LPS, 863+/-182 pg/mL; U-74389G, 369+/-54 pg/mL [p < .05]).

Conclusions: The study demonstrated that administration of U-74389G, which has radical-scavenging and membrane-stabilizing properties, decreased TNF-alpha release during endotoxemia. Thus, 21-aminosteroids may lend themselves to evaluation in the treatment of septic states.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Animals
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use*
  • Endotoxemia / drug therapy*
  • Endotoxemia / metabolism*
  • Enzyme-Linked Immunosorbent Assay
  • Escherichia coli Infections / drug therapy*
  • Escherichia coli Infections / metabolism
  • Escherichia coli*
  • Hemodynamics / drug effects
  • Lipid Peroxidation
  • Lipopolysaccharides*
  • Male
  • Malondialdehyde / metabolism
  • Pregnatrienes / pharmacology
  • Pregnatrienes / therapeutic use*
  • Random Allocation
  • Rats
  • Rats, Wistar
  • Tumor Necrosis Factor-alpha / metabolism*

Substances

  • Antioxidants
  • Lipopolysaccharides
  • Pregnatrienes
  • Tumor Necrosis Factor-alpha
  • U 74389F
  • Malondialdehyde